HPC
BIO icon

HM Payson & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

HM Payson & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7K Hold
50
– – ﹤0.01% 888
2026
Q1 		$13.9K Hold
50
– – ﹤0.01% 881
2025
Q4 		$15.2K Hold
50
– – ﹤0.01% 876
2025
Q3 		$14K Hold
50
– – ﹤0.01% 876
2025
Q2 		$12.1K Hold
50
– – ﹤0.01% 835
2025
Q1 		$12.2K Hold
50
– – ﹤0.01% 848
2024
Q4 		$16.4K Hold
50
– – ﹤0.01% 800
2024
Q3 		$16.7K Hold
50
– – ﹤0.01% 784
2024
Q2 		$13.7K Hold
50
– – ﹤0.01% 812
2024
Q1 		$17.3K Hold
50
– – ﹤0.01% 768
2023
Q4 		$16.1K Hold
50
– – ﹤0.01% 766
2023
Q3 		$17.9K Hold
50
– – ﹤0.01% 756
2023
Q2 		$19K Hold
50
– – ﹤0.01% 737
2023
Q1 		$24K Hold
50
– – ﹤0.01% 688
2022
Q4 		$21K Hold
50
– – ﹤0.01% 668
2022
Q3 		$21K Hold
50
– – ﹤0.01% 689
2022
Q2 		$25K Hold
50
– – ﹤0.01% 680
2022
Q1 		$28K Buy
+50
New +$30.1K ﹤0.01% 682

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HM Payson & Co's BIO Position: Q2 2026 in Review

HM Payson & Co held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 50 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

HM Payson & Co first reported a position in BIO in Q1 2022 and has held it in 18 quarters since. The position peaked at $28K in Q1 2022. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • HM Payson & Co held 50 shares of Bio-Rad Laboratories Class A worth $14.7K as of Q2 2026.
  • HM Payson & Co left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #888 holding.
  • HM Payson & Co first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and has held it in 18 quarters since.
  • HM Payson & Co's Bio-Rad Laboratories Class A position peaked at $28K in Q1 2022.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.